Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

Table 1 Clinical information of subjects

Subject No.	Age ranges (years)	PS^a	Histological type	Primary lesion		Sum of diameter of target lesions (mm)^b	Time from initial diagnosis to enrolled date (months)	Time to progression in prior systemic chemotherapy (months)
Subject No.	Age ranges (years)	PS^a	Histological type	Site	At baseline	Sum of diameter of target lesions (mm)^b	Time from initial diagnosis to enrolled date (months)	Time to progression in prior systemic chemotherapy (months)
Trabectedin group
1	50- < 60	0	EMCS	lower limbs	resected	132.8	94.2	8.7 (IE)
2	60- < 70	1	EMCS	lower limbs	resected	38.4	4.3	1.1 (doxorubicin)
3	<40	0	MCS	neck	conserved	11.3	63.0	NA (neoadjuvant chemotherapy)
4	<40	1	MCS	basal meninges	resected	162.3	82.6	3.7 (doxorubicin)
5	<40	1	MCS	neck	resected	57.3	145.6	NA (neoadjuvant chemotherapy)
Best supportive care group
6	<40	1	MCS	face	conserved	136.8	116.2	7.0 (doxorubicin and cisplatin)
7	<40	0	MCS	pleura	resected	94.6	2.5	0.7 (VDC)
8	<40	1	MCS	retroperi-toneum	resected	209.3	13.4	NA (neoadjuvant chemotherapy)

MCS Mesenchymal chondrosarcoma, EMCS Extraskeletal myxoid chondrosarcoma, PS performance status, NA not applicable, IE ifosfamide and etoposide, VDC vincristine, doxorubicin and cyclophosphamide
^aEastern Cooperative Oncology Group (ECOG) performance status
^bAssessed by central radiology imaging review

ISSN: 1471-2407